+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The anti tumor efficacy of lymphokine activated killer cells and recombinant interleukin 2 in vivo direct correlation between reduction of established metastases and cytolytic activity of lymphokine activated killer cells



The anti tumor efficacy of lymphokine activated killer cells and recombinant interleukin 2 in vivo direct correlation between reduction of established metastases and cytolytic activity of lymphokine activated killer cells



Journal of Immunology 136(10): 3899-3909



Our previous studies demonstrated that the incubation of human peripheral blood lymphocytes or murine splenocytes in recombinant interleukin 2 (RIL 2) resulted in the generation of lymphokine-activated killer (LAK) cells capable of lysing a broad spectrum of fresh tumors in short-term chromium-release assays. Moreover, injections of LAK cells plus RIL 2 were highly effective in eliminating established 3 day metastases in the lung and liver (1-3). We have examined several parameters to define whether or not the cytolytic activity of LAK cells as measured in vitro correlated directly with the in vivo anti-tumor efficacy of adoptively transferred LAK cells. LAK cells plus RIL 2 could mediate marked reductions of established pulmonary metastases in mice rendered T cell deficient by adult thymectomy and lethal, total body irradiation followed by reconstitution with T cell-depleted bone marrow and spleen cells. Thus there was no requirement for additional T lymphocytes of host origin for successful therapy with adoptively transferred LAK cells plus RIL 2. Fresh splenocytes depleted of T cells by anti-Thy-1.2 monoclonal antibody plus complement generated LAK cells that were as highly lytic to fresh tumor in vitro and were as effective in reducing established pulmonary metastases as those generated from untreated or complement-treated splenocytes. Thus the precursor to LAK cells with anti-tumor activity in vitro and in vivo did not express the Thy-1 antigenic marker. In contrast, treatment of LAK effector cells (those generated from a 3-day incubation of fresh, normal splenocytes in RIL 2) with anti-Thy-1.2 antibody plus complement reduced or abolished their in vitro cytolytic activity. However, when combined with the systemic administration of RIL 2, these T cell-depleted, non-lytic LAK cells remained as effective in reducing the number of established pulmonary metastases upon adoptive transfer as untreated or complement-treated lytic LAK cells. Analysis by fluorescence-activated cell sorter revealed the reappearance of the Thy-1 marker in the T cell-depleted, non-lytic LAK cell population after in vitro, incubation of the cells with RIL 2 for an additional 3 to 5 days; in vitro cytolytic activity also returned to normal levels by this time. In vivo exogenous RIL 2 administration for 5 days was responsible for the complete regeneration of lytic activity of adoptively transferred T cell-depleted, non-lytic LAK cells. This was evidenced by the isolation of LAK cells with in vitro cytolytic activity directly from the lungs during regression of pulmonary metastatic foci after LAK cells plus RIL 2 administration. In contrast, mice with established 3 day pulmonary metastases that received T cell-depleted, non-lytic LAK cells plus Hanks' balanced salt solution administration showed no reduction in the numbers of tumor nodules; cells recovered directly from the lungs of these mice failed to have any LAK cell cytolytic activity when tested as effectors against fresh tumor targets in a chromium-release assay. Taken together, our in vitro and in vivo results indicate that Thy-1-positive, cytolytic LAK cells mediate regression of established pulmonary metastases in vivo when combined with the systemic administration of RIL 2.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006601293

Download citation: RISBibTeXText

PMID: 2871106


Related references

The anti tumor effects of interferon in experimental animals. Chandra P (Ed ) Nato Advanced Study Institutes Series, Series A: Life Sciences, Vol 20 Antiviral Mechanisms in The Control Neoplasia; Proceedings, Corfu, Greece, March 15-25, 1978 Xiv+757p Plenum Press: New York, N Y , Usa; London, England Illus P697-702, 1979, 1980

The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma. No to Shinkei 38(3): 265-271, 1986

Combination treatment with insulin and sulfonylurea. Results of a 5-year study. Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 44(9): 261-264, 1989

Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion. Cancer Research 46(4 Pt 1): 1735-1740, 1986

Effect of immunotherapy with a saline phenol extract of allogeneic tumour on E-rosette counts in horn cancer-affected cattle. Australian Veterinary Journal 63(8): 251-253, 1986

Regression of endometriosis following shorter treatment with or lower dose danazol comparison of pretreatment and posttreatment laparoscopic findings in the scandinavian multi center study. Acta Obstetricia et Gynecologica Scandinavica Suppl. (123): 51-58, 1984

Efficacy of intracavernous injection of papaverine and prostaglandin in the diagnosis and treatment of erectile impotence. Revue Medicale de la Suisse Romande 109(4): 291-298, 1989

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Research 46(10): 4973-4978, 1986

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. Journal of Experimental Medicine 157(3): 884-897, 1983

Mechanism of interferon beta-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines. Journal of the National Cancer Institute 87(3): 206-212, 1995

Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits. Journal of Immunology 146(10): 3280-3288, 1991

In vitro expansion of cerebro spinal fluid t cell populations with human t cell growth factor. Neurology 31(4 Part 2): 145, 1981

Reduction of pulmonary hypertension by nitroprusside. International Journal of Clinical Pharmacology and Biopharmacy 15(2): 75-80, 1977

Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity. Cancer Research 48(4): 878-883, 1988

Interleukin 4 il 4 affects both proliferative and differentiative phases of cytotoxic t lymphocyte ctl induction. FASEB Journal 2(4): ABSTRACT 3515, 1988